Journal of vector borne diseases · 2025
Clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) for the treatment of uncomplicated falciparum malaria in different transmission settings in India.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ranjha Ritesh, Baharia Rajendra, Vani H Chalageri, Srivastava Bina, Ahmed Naseem, Sharma Supriya, Mallick Prashant Kumar, Anvikar Anupkumar R, Bharti Praveen Kumar
Аннотация
BACKGROUND OBJECTIVES: In 2010, artesunate and sulfadoxine-pyrimethamine (AS+SP) were adopted as the first-line artemisinin based combination therapy for treatment of uncomplicated Plasmodium falciparum malaria in India. Continuous therapeutic efficacy monitoring of first line anti-malarial drugs is required to update the treatment policy for malaria control and elimination. This study aimed to assess the therapeutic efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) at three sites with different diseases transmission intensity.
METHODS: A 28-day, single-arm, prospective study was conducted to evaluate the clinical and parasitological response to AS+SP. Patients received a six-dose regimen of AS+SP over three days and were monitored for 28 days through clinical and laboratory assessments. Participant recruitment and outcome classification was done as per WHO guidelines for surveillance of anti-malarial drug efficacy.
RESULTS: A total of 170 participants were enrolled and 147 of them completed the follow-up. Adequate clinical and parasitological response (ACPR) was observed in 100% of the study participants who completed the follow-up. 100% fever clearance as well as parasite clearance was observed on day 3.
INTERPRETATION CONCLUSION: This study demonstrated high therapeutic efficacy and a good safety profile for artesunate and sulfadoxine-pyrimethamine at different transmission intensities. This suggests the continuation of the current artemisinin-based combination therapy for the treatment of P. falciparum malaria in India.
METHODS: A 28-day, single-arm, prospective study was conducted to evaluate the clinical and parasitological response to AS+SP. Patients received a six-dose regimen of AS+SP over three days and were monitored for 28 days through clinical and laboratory assessments. Participant recruitment and outcome classification was done as per WHO guidelines for surveillance of anti-malarial drug efficacy.
RESULTS: A total of 170 participants were enrolled and 147 of them completed the follow-up. Adequate clinical and parasitological response (ACPR) was observed in 100% of the study participants who completed the follow-up. 100% fever clearance as well as parasite clearance was observed on day 3.
INTERPRETATION CONCLUSION: This study demonstrated high therapeutic efficacy and a good safety profile for artesunate and sulfadoxine-pyrimethamine at different transmission intensities. This suggests the continuation of the current artemisinin-based combination therapy for the treatment of P. falciparum malaria in India.